

Access to New Medicines in Ireland What's Changing?

Part One | Friday, 19th March 2021

AGENDA

9:00 Welcome, Introductions & Objectives

Brenda Dooley, CEO, AXIS

9:05 Landscape Overview: Pricing and Reimbursement in Ireland

Brenda Dooley, CEO, AXIS

9:35 Expert Elicitation in Irish Reimbursement Applications

Marian Hernon, Associate Director, AXIS

10:00 Break

10:05 Price Discussions in Ireland

Brenda Dooley, CEO, AXIS

10:30 Writing a Compelling Rapid Review Using Local Data

Cillian Copeland, HTA Manager, AXIS

11:00 Break

11:15 BREAKOUT SESSIONS

Option A - Identifying Gaps in the Global Value Dossier

Option B - Constructing a Strong Commercial Offer

Facilitated by Brenda Dooley, CEO and Marian Hernon, Associate Director, AXIS

11:35 Break

11:40  Perspective from the HSE-Corporate Pharmaceutical Unit (CPU)

Ellen McGrath, Incoming Head of the CPU

12:00  Perspective from the National Cancer Control Programme (NCCP)

AnneMarie Defrein, Deputy Chief Pharmacist, NCCP

12:20 Q and A

Moderated by Brenda Dooley, CEO and Marian Hernon, Associate Director, AXIS

12:30 Close of Part One

ELLEN MCGRATH

Incoming Head of the CPU

Ellen McGrath will shortly be appointed as Head of the Corporate Pharmaceutical Unit (CPU) which is the interface between the Health Service Executive (HSE) and the pharmaceutical industry in relation to medicine pricing & reimbursement at a national level. Ellen has been involved in commercial negotiations as well as horizon scanning and service planning for the HSE-PCRS since 2016.



ANNEMARIE DEFREIN

Deputy Chief Pharmacist, NCCP

AnneMarie has spent over 20 years in pharmacy cancer services after graduating from Trinity College Dublin. Before joining the NCCP, she was the Aseptic Unit Manager at St. Vincent's University Hospital for 13yrs and a clinical pharmacist in Beaumont Hospital for 5yrs. She has extensive experience across medical oncology and haemato-oncology, clinical trials and aseptic compounding.

Access to New Medicines in Ireland What's Changing?

Part Two | Wednesday, 24th March 2021

AGENDA

9:00 Welcome Back to Part Two

Brenda Dooley, CEO, AXIS

9:05 Developing a strong HTA submission

Marian Hernon, Associate Director and James Healy, HTA Manager, AXIS

9:30 Oncology Applications

Marian Hernon, Associate Director, AXIS

10:00 Break

10:05 Irish Reimbursement Process for Orphan Medicinal Products

Marian Hernon, Associate Director, AXIS

10:30 The Medicines Management Programme

Brenda Dooley, CEO, AXIS

11:00 Break

11:15 BREAKOUT SESSIONS

Option A - Demystifying the Statistics Used in HTAs

Option B - VBA in Your Cost-effectiveness Model: A Beginners Guide

Facilitated by Niamh Russell, Biostatistician, Cillian Copeland, HTA Manager and James Healy, HTA Manager, AXIS

11:35 Break

11:40 Perspective from a Private Payer



Megan Smith, Head of Medical Strategy, Irish Life Health

12:00 Perspective from Chair of the Rare Diseases Technology Review Committee (RDTRC)



Dr Jerome Coffey, Chair of the RDTRC, Ireland

12:20 Q and A

Moderated by Brenda Dooley, CEO, AXIS and Marian Hernon, Associate Director, AXIS

12:30 Close of Part Two

MEGAN SMITH

Head of Medical Strategy, Irish Life Health

As a qualified and registered physiotherapist, with a master's degree in Medical Science and a MBA, Megan's work experience ranges from work in public and private healthcare, rehabilitation, case management, health insurance and management consulting. Megan leads on Medical Strategy for Irish Life Health, one of Ireland's Private Insurance Providers.



DR JEROME COFFEY

Chair of the RDTRC, Ireland

Dr Jerome Coffey was appointed Chairperson of the HSE's Rare Diseases Medicinal Products Technology Review Committee (RDTRC) in early 2020. He is also Chair of the Board of Ireland's National Cancer Registry, a role he has held since May 2017, and has recently taken on the role of head of the cancer centre at the Mater Private Hospital, Dublin.

